Hutchmed (China) Limited 2021 Annual Report and Notice of AGM (6499F)
23 Mars 2022 - 9:30AM
UK Regulatory
TIDMHCM
RNS Number : 6499F
Hutchmed (China) Limited
23 March 2022
2021 Annual Report and Notice of Annual General Meeting
Hong Kong, Shanghai, & Florham Park, NJ - Wednesday, March
23, 2022: HUTCHMED (China) Limited (" HUTCHMED ") (Nasdaq/AIM: HCM;
HKEX:13) today announces that its 2021 Annual Report together with
the Notice of Annual General Meeting and the Form of Proxy ("AGM
Materials") will be posted to shareholders on March 24, 2022 who
have elected to receive the AGM Materials in printed form. The
documents can also be accessed from the HUTCHMED website (
www.hutch-med.com ).
The 2022 Annual General Meeting ("AGM") will be held at the
Conference Room, 18(th) Floor, Hutchison Telecom Tower, 99 Cheung
Fai Road, Tsing Yi, Hong Kong on Wednesday, April 27, 2022 at 6:00
pm Hong Kong Time (11:00 am London Time).
To safeguard the health and safety of shareholders, HUTCHMED
encourages shareholders to: (i) attend the AGM online and vote by
means of electronic facilities; or (ii) exercise their right to
vote at the AGM by appointing the Chairman of the AGM as their
proxy. Shareholders will be able to view a live webcast of the AGM
through the website of the Company at www.hutch-med.com/event/ .
All registered shareholders will also receive a letter containing
log in details and information on how to access the webcast.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative,
commercial-stage, biopharmaceutical company. It is committed to the
discovery and global development and commercialization of targeted
therapies and immunotherapies for the treatment of cancer and
immunological diseases. It has more than 4,600 personnel across all
its companies, at the center of which is a team of about 1,500 in
oncology/immunology. Since inception it has advanced 12 cancer drug
candidates from in-house discovery into clinical studies around the
world, with its first three oncology drugs now approved and
marketed in China. For more information, please visit:
www.hutch-med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, +1 (917) 570 7340 (Mobile)
Solebury Trout bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
FTI Consulting HUTCHMED@fticonsulting.com
Asia - Zhou Yi, +852 9783 6894 (Mobile)
Brunswick HUTCHMED@brunswickgroup.com
Nominated Advisor
Atholl Tweedie / Freddy Crossley,
Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAFLFFEVVIFFIF
(END) Dow Jones Newswires
March 23, 2022 04:30 ET (08:30 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
